Literature DB >> 7580270

Amyloid goiter in cystic fibrosis.

M H Samuels1, N Thompson, D Leichty, E C Ridgway.   

Abstract

Chronic infectious or inflammatory diseases lead to amyloid infiltration and dysfunction of many organs, including the kidney, liver, heart, and gastrointestinal tract. Subclinical amyloid infiltration of the thyroid gland has been described in over 80% of such patients. However, symptomatic involvement of the thyroid gland by amyloid is rare. We describe a euthyroid patient with cystic fibrosis and widespread amyloidosis who presented with a rapidly enlarging goiter and symptoms of local compression that compromised his pulmonary status. Fine needle aspiration of the goiter was nondiagnostic. At surgery he proved to have replacement of the thyroid gland by amyloid. A review of the literature reveals only five previous cases of amyloid goiter in patients with cystic fibrosis. However, as more patients survive into adulthood, amyloid goiter may become a more common complication of cystic fibrosis. In contrast to other patients with reactive amyloidosis and goiter, patients with cystic fibrosis may require thyroid surgery to relieve airway compression that can compromise pulmonary function.

Entities:  

Mesh:

Year:  1995        PMID: 7580270     DOI: 10.1089/thy.1995.5.213

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  3 in total

1.  Juvenile rheumatoid arthritis with amyloid goiter: report of a case with review of the literature.

Authors:  A Srivastava; M Baxi; S Yadav; A Agarwal; R K Gupta; S K Misra; A Mithal
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

2.  A young patient with recurrent respiratory tract infection and anasarca.

Authors:  Kosar Hussain; Niaz Ahmed Shaikh; Liza Thomas; Mahmoud M Marashi
Journal:  BMJ Case Rep       Date:  2013-11-11

Review 3.  Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report.

Authors:  M Centanni; S Benvenga; I Sachmechi
Journal:  J Endocrinol Invest       Date:  2017-07-10       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.